Our findings were in line with those of a previous study that compared the effectiveness of afatinib and osimertinib in treating patients with NSCLC who had classical EGFR mutations.16 This study investigated 326 osimertinib-treated patients and 224 afatinib-treated patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.